Rallybio Corp (RLYB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 300K 600K 900K Q4 '24: 636K Q1 '25: 848K Q2 '25: 761K Q3 '25: 674K Q4 '25: 858K Q1 '26: 858K Q2 '26: 646K Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '20: -25.3M Q1 '21: -34.3M Q2 '21: -40.2M Q3 '21: -43.4M Q4 '21: -45.6M Q1 '22: -47.1M Q2 '22: -54.2M Q3 '22: -63.1M Q4 '22: -67.9M Q1 '23: -71.9M Q2 '23: -74.4M Q3 '23: -74.9M Q4 '23: -78.9M Q1 '24: -80.3M Q2 '24: -77.3M Q3 '24: -70M Q4 '24: -60.5M Q1 '25: -50.4M Q2 '25: -43.4M Q3 '25: -38.3M Q4 '25: -33.1M Q1 '26: -32.1M Q2 '26: -27.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '20: -26.4M Q1 '21: -35.8M Q2 '21: -42.1M Q3 '21: -45.1M Q4 '21: -47M Q1 '22: -48.2M Q2 '22: -54.7M Q3 '22: -62.9M Q4 '22: -66.7M Q1 '23: -69.5M Q2 '23: -70.5M Q3 '23: -70.5M Q4 '23: -74.6M Q1 '24: -76.3M Q2 '24: -73.9M Q3 '24: -67M Q4 '24: -57.8M Q1 '25: -48.2M Q2 '25: -41.7M Q3 '25: -14.2M Q4 '25: -9M Q1 '26: -7.8M Q2 '26: 45.6M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q2 '21: -37.7M Q3 '21: -42.9M Q4 '21: -45.5M Q1 '22: -47.3M Q2 '22: -48M Q3 '22: -51.9M Q4 '22: -57.3M Q1 '23: -62.3M Q2 '23: -62.1M Q3 '23: -63.9M Q4 '23: -60.3M Q1 '24: -57M Q2 '24: -54M Q3 '24: -51.1M Q4 '24: -49.3M Q1 '25: -44M Q2 '25: -42M Q3 '25: -35M Q4 '25: -29.8M Q1 '26: -27.6M Q2 '26: 26.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q2 '21: -37.9M Q3 '21: -43.2M Q4 '21: -45.9M Q1 '22: -47.6M Q2 '22: -48.4M Q3 '22: -52.1M Q4 '22: -57.3M Q1 '23: -62.3M Q2 '23: -62.2M Q3 '23: -63.9M Q4 '23: -60.3M Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '21: 22.6M Q3 '21: 27.5M Q1 '22: 30.3M Q2 '22: 30.6M Q3 '22: 30.8M Q1 '23: 40.2M Q2 '23: 40.4M Q3 '23: 40.5M Q1 '24: 40.8M Q2 '24: 44.1M Q3 '24: 44.6M Q1 '25: 5.6M Q2 '25: 44.8M Q3 '25: 45.1M Q1 '26: 5.7M Q2 '26: 5.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '21: -1.86 Q1 '22: -1.74 Q2 '22: -1.82 Q3 '22: -2.05 Q4 '22: -2.09 Q1 '23: -2.04 Q2 '23: -1.93 Q3 '23: -1.78 Q4 '23: -1.83 Q1 '24: -1.87 Q2 '24: -1.78 Q3 '24: -1.59 Q4 '24: -10.63 Q1 '25: -11.85 Q2 '25: -11.70 Q3 '25: -11.08 Q4 '25: -1.59 Q1 '26: -1.36 Q2 '26: 6.39 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.